The financing round for Isomorphic, which specialises in developing drugs using artificial intelligence, was led by investors Greenoaks and Sequoia Capital.
Isomorphic Labs’ Drug Design Engine (IsoDDE) is a system that uses different AI models, with the ambition of developing drugs for multiple therapeutic areas. The AI models are combined with the company's researchers to optimise AI-driven drug development into potential candidates.